Protara falls after mid-stage trial data for lead asset in bladder cancer
Source: SeekingAlpha
2026-02-24 14:08:17 ET
More on Protara Therapeutics
- Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Protara Therapeutics: End Of 2025 Proving Eventful Indeed
- Protara, CeriBell rise on FDA breakthrough designations
- Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share
Read the full article on Seeking Alpha
For further details see:
Protara falls after mid-stage trial data for lead asset in bladder cancer
ArTara Therapeutics Inc.
NASDAQ: TARA
TARA Trading
-1.95% G/L:
$5.77 Last:
204,379 Volume:
$5.71 Open:
TARA Latest News
February 23, 2026 05:05:00 pm
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
February 17, 2026 08:24:00 am
The FDA Cleared 50 Oncology Approvals in 2025 and the Pipeline Keeps Accelerating
TARA Stock Data
$335,599,804
47,293,757
3.64%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
